



(51) International Patent Classification:
C07K 16/46 (2006.01) A61K 47/68 (2017.01)

(21) International Application Number:
PCT/US2024/020898

(22) International Filing Date:
21 March 2024 (21.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/454,009 22 March 2023 (22.03.2023) US

(71) Applicant: **EXELIXIS, INC.** [US/US]; 1851 Harbor Bay Parkway, Alameda, CA 94502 (US).

(72) Inventors: **GOGAS, Kathleen**; c/o EXELIXIS, INC., 1851 Harbor Bay Parkway, Alameda, CA 94502 (US). **KANTAK, Seema**; c/o EXELIXIS, INC., 1851 Harbor Bay Parkway, Alameda, CA 94502 (US). **MENDELSON, Brian, Alan**; c/o EXELIXIS, INC., 1851 Harbor Bay Parkway, Alameda, CA 94502 (US). **SARMA, Ganapathy**; c/o EXELIXIS, INC., 1851 Harbor Bay Parkway, Alameda, CA 94502 (US).

(74) Agent: **CAMPBELL, Patricia, A.** et al.; JONES DAY, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DLL3 ANTIBODY-DRUG CONJUGATES AND USES THEREOF

(57) Abstract: The present disclosure provides DLL3 antibody-drug conjugates and uses thereof.




FIG. 1A

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*